License and Asset Purchase Agreements - Additional Information (Details) - USD ($) $ in Thousands		1 Months Ended						3 Months Ended		9 Months Ended
	Sep. 28, 2022	Jul. 31, 2022	Aug. 31, 2021	Jan. 31, 2021	Oct. 31, 2020	Nov. 30, 2019	Aug. 31, 2019	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Feb. 28, 2019
License and Asset Purchase Agreements [Line Items]
Cost of product sold								$ 22,959	$ 14,604	$ 56,596	$ 37,701
Accrued Sales Based Trademark and Royalties								20,944		20,944		$ 16,396
All Countries Excluding Greater China | HBS-102 | Asset Purchase Agreement with ConSynance Therapeutics [Member]
License and Asset Purchase Agreements [Line Items]
Consideration transferred			$ 3,500
Payment for intellectual property upon preclinical milestones			1,750
Payment for intellectual property upon developmental milestones			19,000
Payment for intellectual property upon sales milestones			110,000
Payment for intellectual property upon regulatory milestones			$ 44,000
Bioprojet
License and Asset Purchase Agreements [Line Items]
Licensing agreement milestone fees							$ 2,000
License agreement milestone payments paid						$ 75,000	2,000
License agreement, additional milestone payment due							102,000
Accrued Sales Based Trademark and Royalties								20,944		20,944		$ 16,396
Bioprojet | Upon Acceptance by FDA of Pitolisant's
License and Asset Purchase Agreements [Line Items]
License agreement, milestone payment due													$ 50,000
License agreement, upfront non-refundable licensing fees paid		$ 30,000
License agreement, maximum additional milestone payment due		$ 155,000
Bioprojet | Upon Acceptance by FDA of Pitolisant's | Research and Development Expense
License and Asset Purchase Agreements [Line Items]
License agreement, upfront non-refundable licensing fees paid	$ 30,000
Bioprojet | Upon FDA Approval of WAKIX
License and Asset Purchase Agreements [Line Items]
License agreement, milestone payment due							77,000
Licensing agreement milestone fees							$ 2,000
License agreement milestone payments paid				$ 100,000	$ 2,000
Bioprojet | Sales-based, Trademark and Tiered Royalties
License and Asset Purchase Agreements [Line Items]
Cost of product sold								$ 20,944	$ 13,202	51,741	$ 34,561
Bioprojet | United States
License and Asset Purchase Agreements [Line Items]
Amount of Aggregate Net Sales Attaining										500,000
Bioprojet | Attaining $500,000 Aggregate Net Sales | United States | Upon FDA Approval of WAKIX
License and Asset Purchase Agreements [Line Items]
Final payment paid										$ 40,000